Awards and Recognition - In March 2024, the company was awarded "Top 100 Beauty Brands in China 2023" by Forbes[4]. - The company was recognized as a "National Quality Integrity Demonstration Enterprise" and "Leading Enterprise in Quality of Recombinant Humanized Collagen Industry" by the China Quality Inspection Association in March 2024[4]. - The company’s small molecule recombinant type XVII humanized collagen won the PCHi 2024 Award in March 2024[4]. - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" enterprise and a key player in the synthetic biology industry chain in Shanxi Province[43]. Financial Performance - The company's operating revenue for 2024 reached ¥1,442,831,399.69, representing an 84.92% increase compared to ¥780,260,212.25 in 2023[27]. - The net profit attributable to shareholders for 2024 was ¥732,301,620.38, a significant increase of 144.27% from ¥299,796,292.39 in 2023[27]. - The gross profit margin improved to 92.02% in 2024, up from 90.16% in 2023[27]. - Total assets increased by 43.33% to ¥2,056,073,416.98 in 2024, compared to ¥1,434,538,371.98 at the end of 2023[29]. - The company's net assets attributable to shareholders rose by 60.98% to ¥1,535,213,828.42 in 2024, up from ¥953,673,356.15 in 2023[29]. - The cash flow from operating activities for 2024 was ¥767,155,394.37, reflecting a 159.55% increase from ¥295,566,382.43 in 2023[29]. - The basic earnings per share for 2024 was ¥8.27, a 131.65% increase from ¥3.57 in 2023[27]. - The company reported a total liabilities increase of 9.03% to ¥524,865,480.46 in 2024, compared to ¥481,407,169.13 in 2023[29]. Research and Development - The company obtained 20 invention patents in 2024, including 6 international patents[4]. - The company completed the development of three forms of recombinant type III humanized collagen, including freeze-dried fibers, solutions, and gels, marking a significant breakthrough in safety and effectiveness[41]. - The company has filed for 20 new invention patents during the reporting period, including 6 international patents, enhancing its original innovation capabilities[42]. - The company established two new subsidiaries focused on recombinant human collagen products for tumor treatment and ophthalmology, enhancing its R&D capabilities[88]. - The company has established six core technology platforms, including high-throughput automated functional screening and AI prediction for collagen structure[183]. Market and Industry Trends - The global biomaterials market is expected to reach USD 47.5 billion by 2025, with a CAGR of 6.0%, primarily driven by applications in the medical field[50]. - The Chinese recombinant collagen product market is projected to grow at a CAGR of 44.93%, reaching CNY 58.57 billion by 2025 and CNY 219.38 billion by 2030[51]. - The medical device industry in China generated approximately 1,160 billion RMB in revenue in 2023, a decrease of about 6.4% from the previous year, accounting for around 27%-28% of global revenue in this sector[106]. Corporate Governance and Compliance - The company has a total of 9 board members and 3 supervisors, ensuring a diverse governance structure[148]. - The company has a clear and transparent cash dividend policy that protects the rights of minority shareholders[143]. - The company has engaged qualified third parties to handle hazardous waste generated during its research and development processes[194]. - The company has complied with all legal and regulatory requirements in its operational decisions and governance practices[199]. Environmental and Social Responsibility - The company has established a comprehensive environmental protection strategy, ensuring low carbon emissions and effective waste management during production processes[105]. - The company has implemented environmental protection measures and has not faced any major safety production accidents or penalties from environmental authorities during the reporting period[193]. - The company has initiated a public welfare project to provide medical assistance to over 20 children with cleft lip and palate[104]. Shareholder Information - The total number of ordinary shares increased from 68,086,000 to 88,511,800 after a stock dividend of 3 shares for every 10 shares held and a cash dividend of 10 RMB per 10 shares[130]. - The largest shareholder, Yang Xia, holds 52,128,440 shares, representing 58.89% of the total shares, with a decrease of 12,029,640 shares during the period[131]. - The company has no pledged or judicially frozen shares among the top ten shareholders[133]. Employee and Workforce Development - The total number of R&D personnel increased from 173 to 212, with the proportion of R&D staff to total employees rising from 23.70% to 25.76%[93]. - The total number of employees with a master's degree increased by 26.79% to 142[158]. - The company has implemented targeted training programs to enhance employee skills and knowledge[159]. Product Development and Innovation - The company is focused on developing various medical devices and functional skincare products based on its core component, recombinant type A humanized collagen[44]. - The company is developing a broad-spectrum antiviral drug aimed at treating coronavirus infections, with clinical trials already completed[96]. - The company plans to expand its product offerings in the field of recombinant human collagen, which is expected to enhance its competitive edge[95].
锦波生物(832982) - 2024 Q4 - 年度财报